Abstract Search

ea0081p678 | Pituitary and Neuroendocrinology | ECE2022

Treatment of cushing’s disease (CD) after primary failure of pituitary surgery or recurrence: evaluation of long-term control by medical treatment

Ghalawinji Adel , Cristante Justine , Lefournier Virginie , Chaffanjon Philippe , muller Marie , Gay Emmanuel , Olivier Chabre

Introduction: Pituitary surgery is the first line treatment for most patients with Cushings disease (CD) but after failure or recurrence after surgery 3 main strategies can be proposed: medical treatment (MT), a 2 nd pituitary surgery, bilateral adrenalectomy (BA). Pituitary radiotherapy is a 4th strategy, generally combined with one of the 3 others. Medical treatment (MT) emerges as an attractive strategy but there are little data on long-term control after f...

0 shares

ea0022p383 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

Raverot Gerald , Sturm Nathalie , De Fraipont Florence , Caron Philippe , Muller Marie , Cortet-Rudelli Christine , Salenave Sylvie , Assaker Richard , Dufour Henry , Gaillard Stephan , Francois Patrick , Jouanneau Emmanuel , Bernier Michele , Figarella-Branger Dominique , Maurage Claude-Alain , Trouillas Jacqueline , Borson-Chazot Francoise , Brue Thierry

Context: To date ten publications reporting only 16 patients with pituitary aggressive tumors or carcinomas treated with temozolomide are available. Expression of O6-methylguanine-DNA-methyltranferase (MGMT), a DNA repair protein implicated in the resistance to temozolomide, was studied in only 10 out of these 16 patients. It has been suggested that low expression of MGMT could predict temozolomide efficacy.Objective: The aim of this st...

0 shares

Endocrine Abstracts

Treatment of cushing’s disease (CD) after primary failure of pituitary surgery or recurrence: evaluation of long-term control by medical treatment

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

BiosciAbstracts